信迪利单抗联合吉西他滨化疗对肺鳞癌患者近期疗效、血清肿瘤标记物及VEGF水平的影响  

Effect of Sintilimab Combined with Gemcitabine Chemotherapy on Short-term Efficacy,Serum Tumor Markers and VEGF Levels in Patients with Lung Squamous Cell Carcinoma

作　　者：叶忠桂 YE Zhonggui(The Second Hospital of Longyan City,Fujian Province,Longyan 364000,China)

机构地区：[1]福建省龙岩市第二医院,福建龙岩364000

出　　处：《中国医学创新》2022年第34期126-130,共5页Medical Innovation of China

摘　　要：目的:探讨肺鳞癌患者采用信迪利单抗联合吉西他滨化疗对近期疗效、血清肿瘤标记物及血管内皮细胞生长因子(VEGF)水平的影响。方法:选取2020年6月-2021年12月龙岩市第二医院收治的84例肺鳞癌患者,根据随机摸球法将其分成观察组(n=42)与对照组(n=42)。对照组采用吉西他滨和顺铂化疗,观察组采用信迪利单抗联合吉西他滨化疗。比较两组近期疗效、血清肿瘤标记物、VEGF、不良反应发生情况、生活质量。结果:观察组客观有效率(ORR)较对照组更高(P<0.05)。治疗后,两组癌抗原125(CA125)、癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌相关性抗原(SCC)、VEGF水平均低于治疗前,且观察组较对照组更低(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。两组治疗后肺癌生活质量专用问卷(QOL-LC13)评分均低于治疗前,与对照组相比,观察组明显更低(P<0.05)。结论:信迪利单抗联合吉西他滨化疗应用于肺鳞癌患者治疗中,可提高近期疗效,改善机体肿瘤标记物与VEGF水平,促进生活质量提高,避免加重患者不良反应。Objective:To investigate the effect of Sintilimab combined with Gemcitabine chemotherapy on short-term efficacy,serum tumor markers and vascular endothelial growth factor(VEGF)levels in patients with lung squamous cell carcinoma.Method:A total of 84 patients with lung squamous cell carcinoma who were treated in the Second Hospital of Longyan City from June 2020 to December 2021 were selected,they were divided into observation group(n=42)and control group(n=42)according to random touch ball method.The control group received Gemcitabine combined with Cisplatin chemotherapy,the observation group was treated with Sintilimab combined with Gemcitabine chemotherapy.The short-term efficacy,serum tumor markers,VEGF,occurrence of adverse reactions,and quality of life were compared between the two groups.Result:The objective response rate(ORR)in the observation group was higher than that in the control group(P<0.05).After treatment,carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)and cytokeratin 19 fragment antigen 21-1(CYFRA21-1),squamous cell carcinoma-related antigen(SCC)and VEGF levels in both groups were lower than those before treatment,those in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The QOL-LC13 scores after treatment in both groups were lower than those before treatment,that in the observation group was lower than that in the control group(P<0.05).Conclusion:Sintilimab combined with Gemcitabine chemotherapy in the treatment of patients with lung squamous cell carcinoma can improve the short-term efficacy,improve the level of tumor markers and VEGF,improve the quality of life,and avoid aggravating the adverse reactions of patients.

关 键 词：信迪利单抗 吉西他滨化疗 肺鳞癌 血清肿瘤标记物 

分 类 号：R734.2[医药卫生—肿瘤]